




"Achondroplasia Gladiator"—  
Bibliotheque Nationale, Paris

# INTRODUCTION TO TERATOLOGY

**Embryology** is the study of normal intrauterine embryonic or fetal development.

**Teratology** is the study of birth defects, and a **teratogen** is something that either induces or amplifies abnormal embryonic or fetal development and causes birth defects.



## Historical context

τέρας (Greek) *teras* = monster

Everything looking abnormal





## Historical context

Since the 17<sup>th</sup> century related to abnormal births (development)




- **W. Harvey** (1578–1657) - used the term "developmental arrest",
- **C.F. Wolff** (1733–1794) - in his study on the intestine, the term "germ layer" was coined that has been in use to this day,
- **A. von Haller** (1708–1777) - was first to describe the development of the chicken heart,
- **I.G. de Saint-Hillaire** (1805–1861) - was first to introduce the term "teratology",
- **C. Dareste** (1822–1899) - discussed the modes of artificial induction of monstrosities (particularly by mechanical impulses during incubation of hen eggs),
- **R. Virchow** (1821–1902) - gathered a unique collection of rare developmental disorders of the human body in the "Museum of Pathology" in the Berliner hospital Charité,
- **E. Schwalbe** (1906–1999) - defined the expression "teratogenic termination point",
- **CH.R. Stockard** (1879–1936) - introduced the term "critical period".



## What is a teratogen?

- X-Rays
- Lipid diet
- Hypovitaminosis
- Sex hormones
- Virus infection
- Chemical substances (NaBr, retinoid)
- Drugs (aminopterin, thalidomide, medications)
- Recreational drugs, alcohol
- Environmental pollutant (methyl mercury, agrochemicals)



# INTRODUCTION TO TERATOLOGY

## Teratogens around us

**physical** ionizing irradiation (UV, RTG,  $\alpha$ ,  $\beta$ ,  $\gamma$ ), temperature, mechanical factors (amniotic bands, pes equinus, ...)

**chemical** pharmacological drugs (antibiotics, antiepileptics, anticoagulants, cytostatics) solvents, alcohol, heavy metals, organometals, ...

**biological** pathogens (virus), disease of mother (diabetes, myasthenia gravis, PKU)





## How to identify a teratogen?

**<5%**


- Environmental
- Intrauterine infections
- Metabolic disorder of mother
- Drugs and medications
- Radiation

**20-25%**

Genetical

**65-75%**

Multifactorial or unknown





## What does a teratogen do?

- Disrupts fine molecular or metabolic pathways
- **Intra uterine growth retardation**
- **Failure of histogenesis, organogenesis**
- **Embryonic/fetal death**




# INTRODUCTION TO TERATOLOGY

## How to identify a teratogen?

- **Animal studies**
- **Observations from human exposure**


### *Koch's Postulates in microbiology:*

- *The microorganism must be found in abundance in all organisms suffering from the disease, but should not be found in healthy organisms.*
- *The microorganism must be isolated from a diseased organism and grown in pure culture.*
- *The cultured microorganism should cause disease when introduced into a healthy organism.*
- *The microorganism must be reisolated from the inoculated, diseased experimental host and identified as being identical to the original specific causative agent.*




### **"Koch's Postulates" adapted for teratology:**

- The agent must be present during the critical stage of development.
- The agent produces a particular pattern of birth defects in animal studies.
- The agent crosses the placenta and there is a dose-response relationship.
- There is an abrupt increase in the frequency of a particular defect (syndrome).
- The increase of defects is associated with the use of a new drug or the to a chemical or environmental change.
- There is an absence of other factors to explain the observations.
- The mechanism of teratogenesis makes biological sense.



# INTRODUCTION TO TERATOLOGY



**Figure 1** Embryotoxicity of LAR in mouse embryo culture. **(A)** Abnormal embryonic development and anomalies were observed in treatment groups from 0.5 to 2 mg/ml of LAR. Representative embryos are presented. Closed arrows represent the normal structures. Open arrows represent the malformed structures, including microencephaly, opened neural tube defects and sacral regression. Magnification  $\times 25$ . **(B)** Dose–response curve of LAR on embryo development. The minimum concentration of LAR which resulted in a 50% reduction in relative TMS in the embryos was indicated.  $n = 10$  embryos per each LAR concentration.

Molecular Human Reproduction, Vol.18, No.12 pp. 585–592, 2012  
Advanced Access publication on August 19, 2012 doi:10.1093/molehr/gas034

**MHR** ORIGINAL RESEARCH

## Molecular studies of the congenital malformation induced by *Largehead Atractylodes Rhizome*, the most commonly used Chinese medicine for threatened miscarriage

L.Y. Tang<sup>1,†</sup>, L. Li<sup>1,†</sup>, A. Borchert<sup>2</sup>, Clara B.S. Lau<sup>3</sup>, P.C. Leung<sup>3</sup>, and C.C. Wang<sup>1,4,\*</sup>

<sup>1</sup>Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong; <sup>2</sup>Institute of Biochemistry, University of Medicine Berlin, Charité, Berlin, Germany; <sup>3</sup>Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; <sup>4</sup>School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong

\*Correspondence address. Tel: +852-2632-2810; Fax: +852-2634-0008; E-mail: ccwang@cuhk.edu.hk  
Submitted on March 27, 2012; resubmitted on August 3, 2012; accepted on August 9, 2012

## How to identify a teratogen?

- Animal studies
- Observations from human exposure

**Understand the  
biological context**



## Wilson's Six Principles of Teratology (1977)


1. Susceptibility to teratogenesis depends on the **genotype** of the conceptus and the way in which this interacts with environmental factors.
2. Susceptibility to teratogenic agents varies with the **developmental stage** at the time of exposure.
3. Teratogenic agents act in **specific ways** (mechanisms) on developing cells and tissues to initiate abnormal embryogenesis (pathogenesis).
4. The **final manifestations** of abnormal development are death, malformation, growth retardation, and functional disorder.
5. The access of adverse environmental influences to developing tissues depends on the **nature of the influences** (agent).
6. Manifestations of deviant development increase in degree as **dosage** increases from the no-effect to the totally lethal level.

Handbook of  
Teratology

EDITED BY  
JAMES G. WILSON • E. CLARKE FRASER

2 Mechanisms  
and Pathogenesis

# INTRODUCTION TO TERATOLOGY



## Mechanisms of action?

- Mutation
- Chromosomal nondisjunction and breaks Mitotic interference
- Altered nucleic acid integrity or function
- Lack of precursors and substrates needed for biosynthesis
- Altered energy sources
- Enzyme inhibitions
- Osmolar imbalance
- Altered membrane characteristics

**1977**

- Epigenetic control of gene expression
- The effects of small regulatory RNAs
- The imbalance of gene products resulting from submicroscopic alterations of genomic structure such as copy number changes
- Alterations of the cytoskeleton
- Perturbations of the extracellular matrix
- Effects of mechanical forces on embryogenesis
- Disturbances of intracellular or intercellular signalling
- Dysfunction of molecular chaperones
- Effects on the distribution of molecules into subcellular compartments
- Alterations of the integrity of intracellular organelles

**2010**

# INTRODUCTION TO TERATOLOGY

Teratogen	Vrozená vada
<b>Infekce</b>	
rubeola virus	katarakta, glaukom, srdeční vady, hluchota, abnormality zubů
cytomegalovirus	microcephalia, slepota, mentální retardace, odumření fetu
virus Herpes simplex	microphthalmia, microcephalia, retinální dysplasia
virus varicelly	hypoplasie končetin, mentální retardace, svalové atrofie
HIV	microcephalia, růstová retardace
<i>Toxoplasma gondii</i>	hydrocephalia, mozkové kalcifikace, microphthalmia
<i>Treponema pallidum</i>	mentální retardace, hluchota
<b>Fysikální činitele</b>	
rtg záření	microcephalia, spina bifida, rozštěp patra, defekty končetin
hypertermie	anencephalia, spina bifida, mentální retardace, defekty obličeje, srdeční malformace, omphalokéla, defekty končetin
<b>Chemické látky</b>	
thalidomid	defekty končetin, srdeční vady, hluchota, slepota, malformace dalších vnitřních orgánů
aminopterin	anencephalia, hydrocephalia, rozštěp rtu a patra
fentyoin	fetální hydantoinový syndrom, defekty obličeje, mentální retardace
kyselina valproová	defekty nervové trubice, kraniofaciální, srdeční a končetinové vady
trimethadion	rozštěp patra, srdeční, urogenitální a kosterní vady
lithium	srdeční malformace
amfetaminy	rozštěp rtu a patra, srdeční malformace
warfarin	chondrodysplasia, microcephalia
ACE inhibitory*	růstová retardace, odumření fetu
kokain	růstová retardace, microcephalia, abnormality chování, gastroschisis
ethanol	fetální alkoholový syndrom, krátké oční štěrbiny, hypoplasie maxily, srdeční malformace, mentální retardace
isotretinoin (analog vitamínu A)	embryopatie vyvolaná vitamínem A: malé abnormálně tvarované uši, mandibulární hypoplasie, rozštěp patra, srdeční vady, končetinové vady
průmyslová rozpouštědla	nízká porodní hmotnost, kraniofaciální defekty, defekty nervové trubice
organické sloučeniny rtuti	neurologické poruchy připomínající mozkovou obrnu
olovo	růstová retardace, neurologické poruchy

Teratogen	Vrozená vada
<b>Hormony</b>	
androgeny (ethisteron, norethisteron)	maskulinisace ženského zevního genitálu: splynulá labia, hypertrofický klitoris
diethylstilbestrol	hypoplasie varlat, malformace dělohy, vejcovodů a horní části vagíny, v dospělosti karcinom pochvy
diabetes mellitus	řada malformací, hlavně srdečních, defekty nervové trubice, syndrom kaudální regrese spojený s hypoplasii dolních končetin
obesita	srdeční vady, omfalokéla

\* ACE – angiotensin-konvertující enzym

- **Growth retardation**
- **Failure of histogenesis, organogenesis**
- **Embryonic/fetal death**



## How to classify a teratogen?



<https://www.govinfo.gov/content/pkg/FR-2008-05-29/pdf/E8-11806.pdf>



[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf)

**Category A:** Controlled studies in women fail to demonstrate a risk to the fetus in the first trimester (and there is no evidence of a risk in later trimesters), and the possibility of fetal harm appears remote.

**Category B:** Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).

**Category C:** Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal, or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.

**Category D:** There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

**Category X:** Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

## Further reading

### Review Article

## Teratogen Screening: State of the Art

Julia Schumann

*Faculty of Veterinary Medicine, Institute of Physiological Chemistry, University of Leipzig, Leipzig, Germany*

**Corresponding author:**  
Julia Schumann, Ph.D.,  
Institute of Physiological  
Chemistry, Faculty of  
Veterinary Medicine, University  
of Leipzig, Leipzig, Germany  
**Tel:** +49 341 9738107  
**Fax:** +49 341 9738119  
**E-mail:**  
julia.schumann@vmf.uni-  
leipzig.de  
**Received:** 17 Jun 2010  
**Accepted:** 9 Aug 2010

### Abstract

Due to the number of new substances coming into use every year and the increasing amounts of chemicals, which are introduced into the environment, there is a high demand for a rapid, reliable and cost-effective method for detection of developmental toxicity. To meet this challenge various *in vitro* techniques have been established additional to *in vivo* animal testing. This review introduces the techniques in existence at the moment. Requirements on an ideal *in vitro* teratogenicity test system are stated, and the advantages and disadvantages of the present methods are discussed.

*Avicenna J Med Biotech 2010; 2(3): 115-121*

**Keywords:** Animal testing alternatives, Cell culture techniques, Teratogens










# CASE STUDY

## Countries and territories showing historical time-line of Zika virus spread (1947 - 2016)



## Evidence for ZIKV induced microcephaly?



Baby with Typical Head Size



Baby with Microcephaly



Baby with Severe Microcephaly

## How to identify a new teratogen?

- Observations from human exposure
- Epidemiology – Bradford Hill criteria
- Understand the biological context – transmission in ecosystem
- Mechanism of action
- Validate on animals

# CASE STUDY

## Bradford Hill criteria



**Strength** (effect size): A small association does not mean that there is not a causal effect, though the larger the association, the more likely that it is causal.

**Consistency** (reproducibility): Consistent findings observed by different persons in different places with different samples strengthens the likelihood of an effect.

**Specificity**: Causation is likely if there is a very specific population at a specific site and disease with no other likely explanation. The more specific an association between a factor and an effect is, the bigger the probability of a causal relationship.

**Temporality**: The effect has to occur after the cause (and if there is an expected delay between the cause and expected effect, then the effect must occur after that delay).

**Biological gradient**: Greater exposure should generally lead to greater incidence of the effect. However, in some cases, the mere presence of the factor can trigger the effect. In other cases, an inverse proportion is observed: greater exposure leads to lower incidence.

**Plausibility**: A plausible mechanism between cause and effect is helpful (but Hill noted that knowledge of the mechanism is limited by current knowledge).

**Coherence**: Coherence between epidemiological and laboratory findings increases the likelihood of an effect.

**Experiment**: "Occasionally it is possible to appeal to experimental evidence".




**Analogy**: The use of analogies or similarities between the observed association and any other associations.

**Reversibility**: If the cause is deleted then the effect should disappear as well.




# CASE STUDY

## ZKV transmission



## ZIKV mechanism of action



## Validation in animal model

- Failure of placental barrier
- Brain damage



<https://www.cidrap.umn.edu/news-perspective/2016/05/animal-studies-detail-marked-zika-damage-developing-brains>

## Take home message

- Teratology, teratogens → From Koch's postulates to Wilson's principles
- Mechanisms of action → any embryology and/or cell biology textbook
- Classification & clinical examples → any embryology textbook, FDA (EU) categories
- Identification, validation → ZIIKA forest virus story & Bradford Hill criteria

## Further reading:

- Friedman JM. The Principles of Teratology: Are They Still True? Birth Defects Research (Part A): Clinical and Molecular Teratology. 2010. 88:766–768.
- Schumann J. Teratogen Screening: State of the Art. Avicenna J Med Biotechnol. 2010. 2(3): 115–121.
- Varga I. Embryology Teaching: An Often-neglected Part of the Medical Curriculum. Rev Arg de Anat Clin. 2017. 9(2):47-51.
- Ujhazy et al. Teratology – past, present and future. Interdiscip Toxicol. 2012. 5(4): 163–168.



## Not every genetic anomaly results in a malfunction



X



RESEARCH

Leaf Trait Coloration in White Clover  
and Molecular Mapping of the Red Midrib  
and Leaflet Number Traits

Rebecca M. Tashiro, Yuanhong Han, María J. Monteros, Joseph H. Bouton, and Wayne A. Parrott\*

# Thank you for attention